Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirukumab versus placebo in anti-TNF-refractory rheumatoid arthritis
NL-OMON39738Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Sirukumab with Placebo (2 arms). Primary endpoint: ACR20 response at Week 16. Started Jul 2013; status: active, not recruiting.
02
Drugs
sirukumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NL-OMON39738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39738.